﻿<?xml version="1.0" encoding="utf-8"?><?xml-stylesheet title="XSL_formatting" type="text/xsl" href="cms1260795.aspx"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><language>en-gb</language><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><lastBuildDate>Sat, 10 May 2008 02:36:09 GMT</lastBuildDate><title><![CDATA[aidsmap.com news feed : aidsmap news]]></title><description><![CDATA[aidsmap.com news feed : aidsmap news]]></description><copyright>Copyright NAM 2008</copyright><link>http://www.aidsmap.com</link><atom:link href="http://www.aidsmap.com/cms1260794.aspx" rel="self" type="application/rss+xml" /><image><title><![CDATA[aidsmap.com news feed : aidsmap news]]></title><url>http://www.aidsmap.com/files/file1002517.gif</url><link>http://www.aidsmap.com</link><width>122</width><height>44</height></image><ttl>15</ttl><item><title><![CDATA[Does tenofovir increase the risk of efavirenz-associated liver side-effects?]]></title><link>http://www.aidsmap.com/en/news/F459EAFC-6F8F-4AF3-B16D-28CFE436E57A.asp</link><author>Michael Carter</author><guid isPermaLink="false">F459EAFC-6F8F-4AF3-B16D-28CFE436E57A</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[Italian investigators have reported three cases which suggest that treatment with tenofovir (Viread) may increase the risk of liver side-effects caused by efavirenz (Sustiva). The reports are published in the May 11th edition of AIDS. 
]]></description><category>Changing treatments news</category><category>Hepatitis news</category><category>Palliative care news</category><category>Side-effects news</category></item><item><title><![CDATA[Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows]]></title><link>http://www.aidsmap.com/en/news/7CDD9DFC-54FD-49C6-9BB6-AD3313B0C9DB.asp</link><author>Michael Carter</author><guid isPermaLink="false">7CDD9DFC-54FD-49C6-9BB6-AD3313B0C9DB</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[The majority of patients with resistance to existing NNRTIs will benefit from treatment with etravirine (Intelence), a new, powerful NNRTI with a high barrier to resistance, according to a UK study published in the May 11th edition of AIDS. The investigators believe that the “next generation of NNRTIs, including etravirine, will play an important future role in sequencing HIV-infected patients who have acquired NNRTI resistant virus.”
]]></description><category>New drugs news</category><category>Resistance news</category></item><item><title><![CDATA[HIV reduces body's ability to control hepatitis C replication]]></title><link>http://www.aidsmap.com/en/news/58257C7C-AB10-418A-8F74-BADFBE0D78EA.asp</link><author>Adam Legge</author><guid isPermaLink="false">58257C7C-AB10-418A-8F74-BADFBE0D78EA</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[HIV infection significantly impairs the body’s ability to keep the replication of the hepatitis C virus (HCV) under control when coinfection occurs, says an international group of researchers in an article published in the June 1st edition of the Journal of Infectious Diseases (now online).
]]></description><category>Hepatitis news</category></item><item><title><![CDATA[BHIVA: Many patients and clinicians still need educating about the benefits of treatment]]></title><link>http://www.aidsmap.com/en/news/3E98C8D7-0FBD-4B1B-8F39-A55AE3FA12B6.asp</link><author>Edwin J. Bernard</author><guid isPermaLink="false">3E98C8D7-0FBD-4B1B-8F39-A55AE3FA12B6</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[Both HIV-positive individuals and their clinicians require further education around the benefits of earlier initiation of therapy, and better understanding of the risks of treatment interruption, according to a Health Protection Agency (HPA) study presented to the 14th Annual British HIV Association (BHIVA) Conference last month in Belfast. 
]]></description><category>Adherence news</category><category>Conference news</category><category>UK news</category><category>Starting treatment news</category><category>Palliative care news</category><category>Treatment access news</category><category>Treatment interruptions news</category></item><item><title><![CDATA[Insulin resistance may predict risk of cardiovascular disease in HIV]]></title><link>http://www.aidsmap.com/en/news/A628C336-7EBE-4008-A3C3-E0F34D6D83AE.asp</link><author>David McLay</author><guid isPermaLink="false">A628C336-7EBE-4008-A3C3-E0F34D6D83AE</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[Insulin resistance may be a strong predictor of cardiovascular disease risk among people with HIV, says a report published in the April 23rd edition of AIDS. According to the study authors, determining the presence of insulin resistance in addition to calculating traditional risk scores may provide a fuller picture of cardiovascular disease risk in this population. 
]]></description><category>Side-effects news</category><category>Lipodystrophy news</category></item><item><title><![CDATA[Planned interruption of highly active antiretroviral therapy does not select drug resistance mutations in HIV-1-infected children]]></title><link>http://www.aidsmap.com/en/news/2B2FBFEF-FDE4-47AB-804F-0F84B6D2A956.asp</link><author>Tom Egwang</author><guid isPermaLink="false">2B2FBFEF-FDE4-47AB-804F-0F84B6D2A956</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[Stopping highly active antiretroviral therapy (HAART) containing two non-nucleoside reverse transcriptase inhibitors (NNRTI) for 9 or 14 days in HIV-1-infected children with viral suppression did not increase the risk of drug resistance, according to the results of a prospective multicentre study published in the May 15th edition of Clinical Infectious Diseases. 
]]></description><category>Children and HIV news</category><category>Resistance news</category><category>Treatment interruptions news</category></item><item><title><![CDATA[African-Americans with HIV have higher risk of aggressive kidney disease]]></title><link>http://www.aidsmap.com/en/news/03175361-06B3-4B6C-9394-D7FA26EE2D90.asp</link><author>Adam Legge</author><guid isPermaLink="false">03175361-06B3-4B6C-9394-D7FA26EE2D90</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[HIV-infected African-Americans who develop kidney disease are more likely to have a more aggressive form of the disease than white people with HIV, say US researchers writing in the June 1st edition of the Journal of Infectious Diseases.
]]></description><category>Palliative care news</category><category>Side-effects news</category></item><item><title><![CDATA[Counselling programme successfully promotes exclusive breast feeding in South Africa]]></title><link>http://www.aidsmap.com/en/news/E5ADE238-8E1F-45E8-8F4D-862388F09C46.asp</link><author>Derek Thaczuk</author><guid isPermaLink="false">E5ADE238-8E1F-45E8-8F4D-862388F09C46</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[A South African cohort study has shown that it is possible to increase rates of exclusive breast feeding among HIV-positive and HIV-negative women and their newborns in KwaZulu-Natal, South Africa. The results of the study are reported in the April 23rd edition of AIDS.
]]></description><category>Women and HIV news</category><category>Africa news</category><category>Children and HIV news</category><category>Mother-to-child transmission news</category></item><item><title><![CDATA[Family-centred clinics can achieve excellent HIV treatment outcomes in children in Africa]]></title><link>http://www.aidsmap.com/en/news/04CDE435-EB2C-4134-999A-A9961CFFC84F.asp</link><author>Michael Carter</author><guid isPermaLink="false">04CDE435-EB2C-4134-999A-A9961CFFC84F</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[A “family-centred” approach to HIV treatment can help achieve excellent treatment outcomes in children receiving antiretroviral therapy in resource-limited countries, according to a letter published in the April 23rd edition of AIDS. 
]]></description><category>Children and HIV news</category><category>Africa news</category><category>Adherence news</category></item><item><title><![CDATA[Dual class drug resistance present in two-thirds of South African HIV cohort on failing ART]]></title><link>http://www.aidsmap.com/en/news/201B0F04-7792-4640-BA0B-D7C823E5874E.asp</link><author>Keith Alcorn</author><guid isPermaLink="false">201B0F04-7792-4640-BA0B-D7C823E5874E</guid><pubDate>Sat, 10 May 2008 02:36:09 GMT</pubDate><image /><description><![CDATA[Almost two-thirds of individuals failing first-line antiretroviral therapy (ART) in a KwaZulu-Natal cohort had resistance to drugs from two classes, and one-third had at least one mutation that could reduce response to the entire nucleoside analogue class, researchers from the South African Resistance Cohort Study Team report in the May 15th edition of Clinical Infectious Diseases. 
]]></description><category>Changing treatments news</category><category>Africa news</category><category>Resistance news</category></item></channel></rss>